AZ Clears Out Three Respiratory Drugs With Sale To Covis
The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.
The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.